Startups

MindMaze Therapeutics

Geneva, Switzerland

MindMaze Therapeutics Holding SA, public successor listed on SIX as MMTX. Formed through the December 2025 Relief Therapeutics/NeuroX business combination following transfer of strategic MindMaze assets. Zach Henderson is current CEO; historical MindMaze funding is separate.

Team

Alexandre CapetChief Operating & Strategy Officer

Frédéric CondoloTechnology & AI lead

Jeremy MeinenCFO

Martin ReissNonexecutive director

Olaf BlankeNonexecutive director

Walid HannaNonexecutive chair

Zach HendersonCEO

Investments

No investment rounds on record yet.

team@apexlogos.ai2 days ago
RELATED
team@apexlogos.ai2 days ago
BCI research snapshot, reviewed 2026-10-06. Company identity: MindMazeTherapeutics. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # MindMaze — original group and publicly listed successor Research date / sources accessed: **2026-10-06**. Review document only; no database mutations. ## Entity and status audit MindMaze is a real neurotechnology brand, founded by Tej Tadi in 2012, but the pasted standalone private company entry is materially outdated. The [successor’s timeline](https://mindmazetherapeutics.com/about/mindmaze-therapeutics/) and [2025 transaction presentation](https://mindmazetherapeutics.com/wp-content/uploads/2025/12/MindMaze-Therapeutics-Corporate-Presentation-Oct-2025.pdf) identify its origins and restructuring. [Definitive agreement, 2025-10-08](https://mindmazetherapeutics.com/relief-therapeutics-and-neurox-successor-to-mindmaze-sign-definitive-agreement-for-business-combination/) explains NeuroX acquired strategic assets of MindMaze Group SA and MindMaze SA, including IP and brand, through a pre-pack during the debt moratorium. [2026 corporate update](https://mindmazetherapeutics.com/mindmaze-therapeutics-publishes-2025-annual-report-and-corporate-update/) confirms the December 2025 business combination with Relief Therapeutics and public successor **MindMaze Therapeutics Holding SA, SIX: MMTX**, headquartered in Geneva, Switzerland. Official URL: [mindmazetherapeutics.com](https://mindmazetherapeutics.com/). Original group liquidation is indicated by reproduced Swiss registry notices ([registry-derived entry](https://www.pappers.ch/it/company/mindmaze-group-sa-en-liquidation-CHE477979617), bankruptcy effective 2026-04-20); this secondary registry mirror is supporting evidence, not the original registry filing. Verify original legal entity directly in the Swiss registry before importing a precise dissolution date. Do not interpret continued brand operations as continued solvency of the original group. | Pasted claim | Validated outcome | |---|---| | Lausanne HQ | Correct historically; current listed successor identifies Geneva. | | Tej Tadi CEO | Founder and historical CEO; current successor CEO is Zach Henderson, appointed March 2026 ([appointment](https://mindmazetherapeutics.com/mindmaze-therapeutics-appoints-healthtech-veteran-zach-henderson-as-ceo-to-accelerate-global-commercial-scale-2/)). | | $348M total | Unverified and cannot be carried across asset transfer/business combination as successor financing. | | ACTIVE | Brand/successor active; original group was restructured and registry mirror reports liquidation. | | Therapeutics platform | Broadly valid, but this is digital neurorehabilitation rather than a commercially available invasive communication BCI. | ## Existing adex match Read-only Org name search found no MindMaze record. Review whether to add two linked records (original group / successor) or a brand alias on the successor. Suggested successor ID `MindMazeTherapeutics`; the original founding year must not be assigned to the Relief-derived legal holding company without qualification. ## Images and team [Direct successor logo](https://mindmazetherapeutics.com/wp-content/themes/mindmaze/images/mindmazetheraputics.png) extracted from official [leadership HTML](https://mindmazetherapeutics.com/investor-relations/board-and-executive-team/); preserve the site's filename spelling. Current roster below comes from that page; Tej Tadi is historical founder, not in current executive roster. | Person | Role / timing | Profile / evidence | Direct profile-picture URL | |---|---|---|---| | Zach Henderson | CEO, current (March 2026 onward) | [Official profile/team](https://mindmazetherapeutics.com/investor-relations/board-and-executive-team/) | [Image](https://mindmazetherapeutics.com/wp-content/uploads/2026/04/MMT-Team-ZH.png) | | Alexandre Capet | Chief Operating & Strategy Officer; CEO December 2025–March 2026 | [Official profile/team](https://mindmazetherapeutics.com/investor-relations/board-and-executive-team/) | [Image](https://mindmazetherapeutics.com/wp-content/uploads/2026/04/MMT-Team-AC.png) | | Jeremy Meinen | CFO, current | [Official profile/team](https://mindmazetherapeutics.com/investor-relations/board-and-executive-team/) | [Image](https://mindmazetherapeutics.com/wp-content/uploads/2026/04/MMT-Team-JM.png) | | Frédéric Condolo | Technology & AI lead, current | [Official profile/team](https://mindmazetherapeutics.com/investor-relations/board-and-executive-team/) | [Image](https://mindmazetherapeutics.com/wp-content/uploads/2026/04/MMT-Team-FC.png) | | Walid Hanna | Nonexecutive chair, current | [Official profile/team](https://mindmazetherapeutics.com/investor-relations/board-and-executive-team/) | [Image](https://mindmazetherapeutics.com/wp-content/uploads/2026/04/MMT-Team-WH.png) | | Martin Reiss | Nonexecutive director, current | [Official profile/team](https://mindmazetherapeutics.com/investor-relations/board-and-executive-team/) | [Image](https://mindmazetherapeutics.com/wp-content/uploads/2026/04/MMT-Team-MR.png) | | Olaf Blanke | Nonexecutive director, current | [Official profile/team](https://mindmazetherapeutics.com/investor-relations/board-and-executive-team/) | [Image](https://mindmazetherapeutics.com/wp-content/uploads/2026/04/MMT-Team-OB.png) | Tej Tadi — historical founder/CEO, [founder/transaction evidence](https://mindmazetherapeutics.com/relief-therapeutics-and-neurox-successor-to-mindmaze-sign-definitive-agreement-for-business-combination/); direct standalone portrait unavailable in inspected current official roster. ## Financing and corporate transactions | Date | Amount / currency | Category | Counterparties / scope | Evidence | |---|---|---|---|---| | 2016-02-17 | USD100M commitments | Historical financing; commitments not proof all received cash | Hinduja Group lead, unnamed family offices | [Issuer original announcement](https://mindmazetherapeutics.com/mindmaze-the-worlds-first-multisensory-computing-platform-raises-commitments-of-100-million-in-new-funding-round/) | | 2021 | USD 125M | Historical original-company financing | Led by AlbaCore | [Company retrospective presentation](https://mindmazetherapeutics.com/wp-content/uploads/2025/12/MindMaze-Therapeutics-Corporate-Presentation-Oct-2025.pdf) | | 2021 | USD 12M, as presentation labels it | Innosuisse grants, separate from equity | Public research support; exact recipient/timing requires grant record | [Same company presentation](https://mindmazetherapeutics.com/wp-content/uploads/2025/12/MindMaze-Therapeutics-Corporate-Presentation-Oct-2025.pdf) | | 2022-02-17 | USD105M | Financing with immediate funds plus financing facility; instrument/fully drawn amount unverified | Concord Health Partners lead; AlbaCore Capital Group, Hambro Perks and unnamed family offices | [Issuer financing announcement](https://mindmazetherapeutics.com/mindmaze-secures-105-million-financing-led-by-concord-health-partners-to-fund-growth-on-heels-of-banner-year-and-initiates-american-hospital-association-partnership/) | | 2025 | Not disclosed as cash funding | Asset transfer / restructuring | NeuroX acquired strategic MindMaze assets | [Definitive agreement](https://mindmazetherapeutics.com/relief-therapeutics-and-neurox-successor-to-mindmaze-sign-definitive-agreement-for-business-combination/) | | December 2025 | Share consideration, not fresh cash VC | Business combination / listing | NeuroX + Relief; 140M shares approved for contribution in kind | [Shareholder approval](https://mindmazetherapeutics.com/relief-therapeutics-shareholders-approve-business-combination-with-neurox/); [completion retrospective](https://mindmazetherapeutics.com/mindmaze-therapeutics-publishes-2025-annual-report-and-corporate-update/) | Historical rounds table is incomplete; no checked cumulative total. The combination’s reported valuation is not capital raised. Review grants, equity and any structured financing independently; do not sum them into $348M. The [2025 annual report](https://mindmazetherapeutics.com/wp-content/uploads/2026/04/MMTX_Annual_Report_2025.pdf) describes SwissNeuroRehab as a CHF11.2M Innosuisse **program**: this is program funding, not proven cash received entirely by MindMaze; the presentation’s USD12M rendering must not become a company equity round. ## Review / import decision Hold original ACTIVE/CEO/total claims. Add successor with brand/history relationship after legal-entity review. The team and logo above belong to the successor, not automatically the original group. Products include the rehabilitation suite and Izar controller; keep regulatory labels product-specific, using [official timeline](https://mindmazetherapeutics.com/about/mindmaze-therapeutics/).